Varicella vaccination: Evidence for frequent reactivation of the vaccine strain in healthy children

Nature Medicine

Volumn 6, Issue 4, 2000, Pages 451-454

  Krause, Philip R ^a   Klinman, Dennis M ^b  

^a Division of Viral Products   (United States)

^b CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHICKENPOX VACCINE; LIVE VACCINE;

ANTIBODY TITER; ARTICLE; CHICKENPOX; CHILD; CHILDHOOD DISEASE; HUMAN; IMMUNIZATION; INFECTION RATE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; STRAIN DIFFERENCE; TREATMENT OUTCOME; VACCINATION; VARICELLA ZOSTER VIRUS;

ADOLESCENT; ANTIBODIES, VIRAL; CHICKENPOX; CHICKENPOX VACCINE; CHILD; CHILD, PRESCHOOL; HEALTH STATUS; HERPESVIRUS 3, HUMAN; HUMANS; INFANT; SPECIES SPECIFICITY; VIRUS ACTIVATION;

HERPES; HERPES ZOSTER; HUMAN HERPESVIRUS 3;

EID: 0034081617     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/74715     Document Type: Article

References (24)

1. Cohen, J.I., Brunell, P.A., Straus, S.E. & Krause, P.R. NIH conference: Recent advances in varicella-zoster virus infection. Ann. Intern. Med. 130, 922-932 (1999).
2. Wharton, M. The epidemiology of varicella-zoster virus infections. Infect. Dis. Clin. North. Am. 10, 571-581 (1996).
3. Straus, S.E. et al. Endonuclease analysis of viral DNA from varicella and subsequent zoster infections in the same patient. N. Engl. J. Med. 311, 1362-1364 (1984).
4. Asano, Y. et al. Experience and reason: Twenty-year follow-up of protective immunity of the Oka strain live varicella vaccine. Pediatrics 94, 524-526 (1994).
5. Krause, P.R. & Klinman, D.M. Efficacy, immunogenicity, safety, and use of live attenuated chickenpox vaccine. J. Pediatr. 127, 518-525 (1995).
6. Weibel, R.E., J, N.B. & Kuter, B.J. Live attenuated varicella vaccine: efficacy trial in healthy children. N. Engl. J. Med. 310, 1409-1415 (1984).
7. Kuter, B. et al. Oka/Merck varicella vaccine in healthy children: final report of a 2-year efficacy study and 7-year follow-up studies. Vaccine 9, 643-647 (1991).
8. Choo, P.W., Donahue, J.G., Manson, J.E. & Platt, R. The epidemiology of varicella and its complications. J. Infect. Dis. 172, 706-712 (1995).
9. Finger, R., Hughes, J., Meade, B., Pelletier, A. & Palmer, C. Age-specific incidence of chickenpox. Public Health Rep. 109, 750-755 (1994).
10. Bernstein, H.H. et al. Clinical survey of natural varicella compared with breakthrough varicella after immunization with live attenuated Oka/Merck varicella vaccine. Pediatrics 92, 833-83 (1993).
11. Varis, T. & Vesikari, T. Efficacy of high-titer live attenuated varicella vaccine in healthy young children. J. Infect. Di. 174, S330-4 (1996).
12. Luby, J., Ramirez-Ronda, C., Rinner, S., Hull, A. & Vergne-Marini, P. A longitudinal study of varicella-zoster virus infections in renal transplant recipients. J. Infect. Dis. 135, 659-663 (1977).
13. Arvin, A., Koropchak, C. & Wittek, A. Immunologic Evidence of re-infection with varicella-zoster virus. J. Infect. Dis. 148, 200-205 (1983).
14. Tomita, H., Tanaka, M., Kukimoto, N. & Ikeda, M. An ELISA study on varicella-zoster virus infection in acute peripheral facial palsy. Acta Otolaryngol. (Stockh.) 446, 10-16 (1988).
15. Scheiermann, N. & Gesemann, M. Anti-HBs antibody kinetics - A 4 year follow-up after hepatitis B vaccination. Zentralbl. Bakteriol. 278, 120-126 (1993).
16. Hope-Simpson, R.E. The nature of herpes zoster: a long-term study and a new hypothesis. Proc. R. Soc. Lond. 58, 9-20 (1965).
17. Ljungman, P. et al. Clinical and subclinical reactivation of varicella-zoster virus in immunocompromised patients. J. Infect. Dis. 153, 840-847 (1986).
18. Wilson, A., Sharp, M., Koropchak, C.M., Ting, S.F. & Arvin, A.M. Subclinical varicella-zoster virus viremia, herpes zoster, and T lymphocyte immunity to varicella-zoster viral antigens after bone marrow transplantation. J. Infect. Dis. 165, 119-26 (1992).
19. Merck & Co. in Physician's Desk Reference 52nd edn. 1762-1765 (Medical Economics, Montvale, New Jersey, 1998).
20. Brunell, P.A., Taylor, J., Geiser, C.F., Frierson, L. & Lydick, E. Risk of herpes zoster in children with leukemia: varicella vaccine compared with history of chickenpox. Pediatrics 77, 53-65 (1986).
21. Hardy, I., Gershon, A.A., Steinberg, S.P. & LaRussa, P. The incidence of zoster after immunization with live attenuated varicella vaccine. N. Engl. J. Med. 325, 1545-1550 (1991).
22. Wasmuth, E.H. & Miller, W.J. Sensitive ELISA for antibody to varicella-zoster virus using purified VZV glycoprotein antigen. J. Med. Virol. 32, 189-193 (1990).
23. Keller, P.M., Lonergan, K., Neff, B.J., Morton, D.A. & Ellis, R.W. Purification of individual varicella-zoster virus (VZV) glycoproteins gpI, gpII, and gpIII and their use in ELISA for detection of V ZV glycoprotein-specific antibodies. J. Virol. Meth. 14, 177-188 (1986).
24. Colton, T. in Statistics in Medicine 153-159 (Little, Brown, Boston, 1974).